阿戈美拉汀与艾司西酞普兰治疗初诊抑郁症的疗效及安全性比较

Comparison of efficacy and safety of agomelatine and escitalopram in the treatment of newly diagnosed depression

目的比较阿戈美拉汀与艾司西酞普兰治疗初诊抑郁症的疗效及安全性。方法选取2019年1月至2021年12月于江西省精神病院初诊的83例抑郁症患者作为研究对象,采取偶奇数字随机法分为A组(n=41)与B组(n=42)。A组采取阿戈美拉汀进行治疗,B组采取艾司西酞普兰进行治疗。比较两组抑郁程度、焦虑程度、临床疗效及安全性。结果B组治疗1周后HAMD-17评分高于A组,治疗2、4、8周后HAMD-17评分均低于A组,差异有统计学意义(P<0.05)。两组治疗前、治疗后各时间点HAMA评分比较差异均无统计学意义。治疗4周后,A组治疗总有效率为58.54%,低于B组的85.71%,差异有统计学意义(P<0.05);治疗8周后,A组治疗总有效率为73.17%,低于B组的88.10%,但差异无统计学意义。治疗后,A组不良反应总发生率为9.76%,B组不良反应总发生率为16.67%,两组不良反应发生率比较差异无统计学意义。结论初诊抑郁症采用艾司西酞普兰治疗的近期(4周)疗效优于阿戈美拉汀,远期(8周)两种药物治疗疗效接近,两者均具有较高的疗效及安全性。

Objective To compare the efficacy and safety of agomelatine and escitalopram in the treatment of newly-diagnosed depression.Methods 83 patients with depression who were newly diagnosed in Jiangxi Mental Hospital from January 2019 to December 2021 were selected as the research subjects,and they were divided into the group A(n=41)and the group B(n=42)by odd-odd number random method.Group A was treated with agomelatine,while group B was given escitalopram.The depression degree,anxiety degree,clinical efficacy and safety were compared between groups.Results After 1 week of treatment,the HAMD-17 score in the group B was higher than that in the group A,and the HAMD-17 scores after 2,4 and 8 weeks of treatment were lower than those in the group A,the difference was statistically significant(P<0.05).There was no statistical difference in HAMA score between the two groups before treatment and at diffierent time points after treatment.after 4 weeks of treatment,the total effective rate of treatment in the group A was 58.54%,which was lower than 85.71%in the group B,the difference was statistically significant(P<0.05).After 8 weeks of treatment,the total effective rate in the group A was 73.17%,which was slightly lower than 88.10%in the group B,but there was no statistical significance between groups.After treatment,the total incidence rate of adverse reactions in group A was 9.76%,and the group B was 16.67%,thus there was no statistical significance in the incidence of adverse reactions between groups.Conclusion The short-term(4 weeks)efficacy of escitalopram in the treatment of newly-diagnosed depression is better than that of agomelatine,and the long-term(8 weeks)efficacy of the two drugs is similar,both drugs have high efficacy and safety.